Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Abbott Laboratories has a consensus price target of $137.12 based on the ratings of 27 analysts. The high is $160 issued by Citigroup on March 4, 2025. The low is $118 issued by JP Morgan on October 20, 2022. The 3 most-recent analyst ratings were released by Raymond James, Piper Sandler, and RBC Capital on April 17, 2025, respectively. With an average price target of $144 between Raymond James, Piper Sandler, and RBC Capital, there's an implied 8.75% upside for Abbott Laboratories from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/17/2025 | Buy Now | 7.24% | Raymond James | Jayson Bedford68% | $132 → $142 | Maintains | Outperform | Get Alert |
04/17/2025 | Buy Now | 9.51% | Piper Sandler | Adam Maeder61% | $133 → $145 | Reiterates | Overweight → Overweight | Get Alert |
04/17/2025 | Buy Now | 9.51% | RBC Capital | Shagun Singh57% | $140 → $145 | Maintains | Outperform | Get Alert |
04/17/2025 | Buy Now | 11.02% | Wells Fargo | Lawrence Biegelsen48% | $136 → $147 | Maintains | Overweight | Get Alert |
04/17/2025 | Buy Now | -4.09% | Morgan Stanley | David Lewis71% | $117 → $127 | Maintains | Equal-Weight | Get Alert |
04/17/2025 | Buy Now | 20.08% | Barclays | Matt Miksic66% | $158 → $159 | Maintains | Overweight | Get Alert |
04/17/2025 | Buy Now | 9.51% | Stifel | Rick Wise73% | $135 → $145 | Maintains | Buy | Get Alert |
04/17/2025 | Buy Now | 3.47% | Jefferies | Matthew Taylor69% | $135 → $137 | Maintains | Hold | Get Alert |
03/10/2025 | Buy Now | 13.28% | B of A Securities | Travis Steed57% | $133 → $150 | Maintains | Buy | Get Alert |
03/04/2025 | Buy Now | 20.84% | Citigroup | Joanne Wuensch74% | $135 → $160 | Maintains | Buy | Get Alert |
03/04/2025 | Buy Now | 16.31% | Goldman Sachs | David Roman40% | $138 → $154 | Maintains | Buy | Get Alert |
01/27/2025 | Buy Now | 19.33% | Barclays | Matt Miksic66% | $149 → $158 | Maintains | Overweight | Get Alert |
01/23/2025 | Buy Now | 1.96% | RBC Capital | Shagun Singh57% | $135 → $135 | Reiterates | Outperform → Outperform | Get Alert |
01/23/2025 | Buy Now | 2.71% | Wells Fargo | Lawrence Biegelsen48% | $133 → $136 | Maintains | Overweight | Get Alert |
01/23/2025 | Buy Now | 1.96% | Stifel | Rick Wise73% | $130 → $135 | Maintains | Buy | Get Alert |
01/23/2025 | Buy Now | 11.77% | UBS | Danielle Antalffy61% | $146 → $148 | Maintains | Buy | Get Alert |
01/21/2025 | Buy Now | 1.96% | RBC Capital | Shagun Singh57% | $135 → $135 | Reiterates | Outperform → Outperform | Get Alert |
11/05/2024 | Buy Now | 12.53% | Barclays | Matt Miksic66% | $143 → $149 | Maintains | Overweight | Get Alert |
10/17/2024 | Buy Now | 4.22% | Bernstein | Lee Hambright69% | $133 → $138 | Maintains | Outperform | Get Alert |
10/17/2024 | Buy Now | 10.26% | UBS | Danielle Antalffy61% | $143 → $146 | Maintains | Buy | Get Alert |
10/17/2024 | Buy Now | -5.6% | Jefferies | Matthew Taylor69% | $120 → $125 | Maintains | Hold | Get Alert |
10/17/2024 | Buy Now | -1.82% | Mizuho | Anthony Petrone64% | $115 → $130 | Maintains | Neutral | Get Alert |
10/17/2024 | Buy Now | 0.45% | Piper Sandler | Adam Maeder61% | $131 → $133 | Maintains | Overweight | Get Alert |
10/17/2024 | Buy Now | -11.64% | Morgan Stanley | David Lewis71% | $107 → $117 | Maintains | Equal-Weight | Get Alert |
10/14/2024 | Buy Now | -2.58% | Raymond James | Jayson Bedford68% | $122 → $129 | Maintains | Outperform | Get Alert |
10/08/2024 | Buy Now | -1.82% | RBC Capital | Shagun Singh57% | $125 → $130 | Maintains | Outperform | Get Alert |
10/08/2024 | Buy Now | -1.82% | Oppenheimer | Suraj Kalia59% | → $130 | Initiates | → Outperform | Get Alert |
10/01/2024 | Buy Now | -6.35% | Evercore ISI Group | Vijay Kumar50% | $120 → $124 | Maintains | Outperform | Get Alert |
09/26/2024 | Buy Now | -9.37% | Jefferies | Raj Denhoy75% | $120 → $120 | Reiterates | Hold → Hold | Get Alert |
09/19/2024 | Buy Now | -1.06% | Piper Sandler | Adam Maeder61% | → $131 | Initiates | → Overweight | Get Alert |
08/27/2024 | Buy Now | -9.37% | Jefferies | Raj Denhoy75% | $112 → $120 | Maintains | Buy | Get Alert |
08/22/2024 | Buy Now | -4.09% | Citigroup | Joanna Wiensch62% | $119 → $127 | Maintains | Buy | Get Alert |
07/29/2024 | Buy Now | 8% | Barclays | Matt Miksic66% | $140 → $143 | Maintains | Overweight | Get Alert |
07/02/2024 | Buy Now | -9.37% | Evercore ISI Group | Vijay Kumar50% | $125 → $120 | Maintains | Outperform | Get Alert |
06/04/2024 | Buy Now | -5.6% | RBC Capital | Shagun Singh57% | $125 → $125 | Reiterates | Outperform → Outperform | Get Alert |
05/30/2024 | Buy Now | -8.62% | Goldman Sachs | David Roman40% | → $121 | Initiates | → Buy | Get Alert |
05/22/2024 | Buy Now | -10.13% | Citigroup | Joanna Wiensch62% | $128 → $119 | Maintains | Buy | Get Alert |
04/22/2024 | Buy Now | 5.73% | Barclays | Matt Miksic66% | $141 → $140 | Maintains | Overweight | Get Alert |
04/18/2024 | Buy Now | -5.6% | RBC Capital | Shagun Singh57% | $128 → $125 | Maintains | Outperform | Get Alert |
04/04/2024 | Buy Now | -5.6% | Evercore ISI Group | Vijay Kumar50% | $120 → $125 | Maintains | Outperform | Get Alert |
04/03/2024 | Buy Now | -3.33% | Citigroup | Joanne Wuensch74% | $126 → $128 | Maintains | Buy | Get Alert |
02/14/2024 | Buy Now | -3.33% | RBC Capital | Shagun Singh57% | $128 → $128 | Reiterates | Outperform → Outperform | Get Alert |
01/26/2024 | Buy Now | 6.49% | Barclays | Matt Miksic66% | $133 → $141 | Maintains | Overweight | Get Alert |
01/25/2024 | Buy Now | -3.33% | RBC Capital | Shagun Singh57% | $128 → $128 | Reiterates | Outperform → Outperform | Get Alert |
01/25/2024 | Buy Now | -4.84% | Citigroup | Joanne Wuensch74% | $123 → $126 | Maintains | Buy | Get Alert |
01/25/2024 | Buy Now | -4.09% | Raymond James | Jayson Bedford68% | $124 → $127 | Maintains | Outperform | Get Alert |
01/11/2024 | Buy Now | -3.33% | RBC Capital | Shagun Singh57% | $119 → $128 | Maintains | Outperform | Get Alert |
01/03/2024 | Buy Now | -6.35% | Raymond James | Jayson Bedford68% | $110 → $124 | Maintains | Outperform | Get Alert |
12/13/2023 | Buy Now | -8.62% | Wells Fargo | Lawrence Biegelsen48% | $116 → $121 | Maintains | Overweight | Get Alert |
12/11/2023 | Buy Now | -7.11% | Citigroup | Joanne Wuensch74% | $122 → $123 | Maintains | Buy | Get Alert |
10/19/2023 | Buy Now | 0.45% | Barclays | Matt Miksic66% | $132 → $133 | Maintains | Overweight | Get Alert |
10/19/2023 | Buy Now | -19.19% | Morgan Stanley | David Lewis71% | $112 → $107 | Maintains | Equal-Weight | Get Alert |
10/19/2023 | Buy Now | -12.39% | Wells Fargo | Lawrence Biegelsen48% | $136 → $116 | Maintains | Overweight | Get Alert |
10/19/2023 | Buy Now | -16.92% | Raymond James | Jayson Bedford68% | $123 → $110 | Maintains | Outperform | Get Alert |
10/02/2023 | Buy Now | -7.86% | Citigroup | Joanne Wuensch74% | $130 → $122 | Maintains | Buy | Get Alert |
07/24/2023 | Buy Now | -0.31% | Barclays | Matt Miksic66% | $127 → $132 | Maintains | Overweight | Get Alert |
07/21/2023 | Buy Now | -15.41% | Morgan Stanley | David Lewis71% | $112 → $112 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
07/21/2023 | Buy Now | -13.15% | Mizuho | Anthony Petrone64% | $110 → $115 | Assumes | Neutral → Neutral | Get Alert |
07/21/2023 | Buy Now | — | Wolfe Research | Mike Polark55% | — | Upgrade | Underperform → Peer Perform | Get Alert |
05/30/2023 | Buy Now | -15.41% | Morgan Stanley | David Lewis71% | → $112 | Assumes | → Equal-Weight | Get Alert |
04/20/2023 | Buy Now | -1.82% | UBS | Matthew Korn45% | $117 → $130 | Maintains | Buy | Get Alert |
04/20/2023 | Buy Now | -7.11% | Raymond James | Jayson Bedford68% | $116 → $123 | Maintains | Outperform | Get Alert |
04/20/2023 | Buy Now | -4.09% | Barclays | Matt Miksic66% | $125 → $127 | Maintains | Overweight | Get Alert |
04/20/2023 | Buy Now | -1.82% | Citigroup | Joanne Wuensch74% | $125 → $130 | Maintains | Buy | Get Alert |
04/17/2023 | Buy Now | -1.82% | BTIG | Ryan Zimmerman70% | $125 → $130 | Maintains | Buy | Get Alert |
04/17/2023 | Buy Now | -12.39% | Raymond James | Jayson Bedford68% | $123 → $116 | Maintains | Outperform | Get Alert |
04/10/2023 | Buy Now | 2.71% | Wells Fargo | Lawrence Biegelsen48% | $140 → $136 | Maintains | Overweight | Get Alert |
04/05/2023 | Buy Now | 2.71% | Wells Fargo | Larry Biegelsen65% | $140 → $136 | Maintains | Overweight | Get Alert |
03/29/2023 | Buy Now | -11.64% | UBS | Danielle Antalffy61% | → $117 | Assumes | → Buy | Get Alert |
01/27/2023 | Buy Now | -5.6% | Barclays | Matt Miksic66% | $122 → $125 | Maintains | Overweight | Get Alert |
01/26/2023 | Buy Now | -5.6% | BTIG | Marie Thibault63% | $120 → $125 | Maintains | Buy | Get Alert |
01/26/2023 | Buy Now | -5.6% | Stifel | Rick Wise73% | $110 → $125 | Maintains | Buy | Get Alert |
01/26/2023 | Buy Now | -7.11% | Raymond James | Jayson Bedford68% | $109 → $123 | Maintains | Outperform | Get Alert |
01/26/2023 | Buy Now | -0.31% | Bernstein | Lee Hambright69% | $125 → $132 | Maintains | Outperform | Get Alert |
01/25/2023 | Buy Now | -19.19% | Wolfe Research | Mike Polark55% | $92 → $107 | Maintains | Underperform | Get Alert |
01/24/2023 | Buy Now | -16.92% | Mizuho | Anthony Petrone64% | $105 → $110 | Maintains | Neutral | Get Alert |
01/06/2023 | Buy Now | 0.45% | Morgan Stanley | Cecilia Furlong49% | $117 → $133 | Maintains | Overweight | Get Alert |
01/04/2023 | Buy Now | -7.86% | Barclays | Matt Miksic66% | $114 → $122 | Maintains | Overweight | Get Alert |
12/13/2022 | Buy Now | -1.82% | TD Cowen | Joshua Jennings57% | $130 → $130 | Maintains | Outperform | Get Alert |
12/12/2022 | Buy Now | -5.6% | Citigroup | Joanne Wuensch74% | $114 → $125 | Maintains | Buy | Get Alert |
10/26/2022 | Buy Now | -20.7% | Mizuho | Anthony Petrone64% | → $105 | Initiates | → Neutral | Get Alert |
10/21/2022 | Buy Now | -13.9% | Barclays | Matt Miksic66% | $118 → $114 | Maintains | Overweight | Get Alert |
10/21/2022 | Buy Now | -17.68% | Raymond James | Jayson Bedford68% | $117 → $109 | Maintains | Outperform | Get Alert |
10/20/2022 | Buy Now | -13.9% | Citigroup | Joanna Wiensch62% | $117 → $114 | Maintains | Buy | Get Alert |
10/20/2022 | Buy Now | -9.37% | BTIG | Marie Thibault63% | $123 → $120 | Maintains | Buy | Get Alert |
10/20/2022 | Buy Now | -16.92% | Stifel | Rick Wise73% | $126 → $110 | Maintains | Buy | Get Alert |
10/20/2022 | Buy Now | -10.88% | JP Morgan | Robbie Marcus65% | $125 → $118 | Maintains | Overweight | Get Alert |
10/20/2022 | Buy Now | -11.64% | Morgan Stanley | Cecilia Furlong49% | $126 → $117 | Maintains | Overweight | Get Alert |
10/20/2022 | Buy Now | -4.84% | RBC Capital | Shagun Singh57% | $132 → $126 | Maintains | Outperform | Get Alert |
10/19/2022 | Buy Now | -16.92% | Evercore ISI Group | Vijay Kumar50% | $114 → $110 | Maintains | Outperform | Get Alert |
10/18/2022 | Buy Now | -10.88% | Barclays | Matt Miksic66% | → $118 | Initiates | → Overweight | Get Alert |
10/17/2022 | Buy Now | -7.11% | BTIG | Ryan Zimmerman70% | $126 → $123 | Maintains | Buy | Get Alert |
10/12/2022 | Buy Now | -16.92% | Jefferies | Matthew Taylor69% | → $110 | Initiates | → Hold | Get Alert |
10/11/2022 | Buy Now | -4.84% | Morgan Stanley | Cecilia Furlong49% | $132 → $126 | Maintains | Overweight | Get Alert |
10/10/2022 | Buy Now | 5.73% | Wells Fargo | Larry Biegelsen65% | $150 → $140 | Maintains | Overweight | Get Alert |
10/09/2022 | Buy Now | 13.28% | Wells Fargo | Larry Biegelsen65% | → $150 | Maintains | Overweight | Get Alert |
10/05/2022 | Buy Now | -11.64% | Citigroup | Joanna Wiensch62% | $123 → $117 | Maintains | Buy | Get Alert |
08/19/2022 | Buy Now | 5.73% | BTIG | Marie Thibault63% | → $140 | Maintains | Buy | Get Alert |
08/04/2022 | Buy Now | 13.28% | Wells Fargo | Larry Biegelsen65% | $155 → $150 | Maintains | Overweight | Get Alert |
07/28/2022 | Buy Now | 1.96% | Argus Research | David Toung68% | $150 → $135 | Maintains | Buy | Get Alert |
The latest price target for Abbott Laboratories (NYSE:ABT) was reported by Raymond James on April 17, 2025. The analyst firm set a price target for $142.00 expecting ABT to rise to within 12 months (a possible 7.24% upside). 34 analyst firms have reported ratings in the last year.
The latest analyst rating for Abbott Laboratories (NYSE:ABT) was provided by Raymond James, and Abbott Laboratories maintained their outperform rating.
The last upgrade for Abbott Laboratories happened on July 21, 2023 when Wolfe Research raised their price target to N/A. Wolfe Research previously had an underperform for Abbott Laboratories.
There is no last downgrade for Abbott Laboratories.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abbott Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abbott Laboratories was filed on April 17, 2025 so you should expect the next rating to be made available sometime around April 17, 2026.
While ratings are subjective and will change, the latest Abbott Laboratories (ABT) rating was a maintained with a price target of $132.00 to $142.00. The current price Abbott Laboratories (ABT) is trading at is $132.41, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.